share_log

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

150 萬美元押注這隻醫療保健股?看看內部人士正在積極買入的這4只細價股
Benzinga ·  05/23 08:47

The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週三收盤下跌超過200點。當內部人士購買或出售股票時,這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息,請訪問Benzinga的內幕交易平台。

Marygold Companies

瑪麗戈德公司

  • The Trade: The Marygold Companies, Inc. (NYSE:MGLD) 10% owner Nicholas & Melinda Gerber Living Trust bought a total of 80,000 shares at an average price of $1.35. To acquire these shares, it cost around $107,760.
  • What's Happening: On May 13, Marygold Companies reported financial results for the three and nine months ended March 31.
  • What Marygold Companies Does: The Marygold Companies Inc is engaged in identifying and acquiring established, profitable, undervalued companies in diverse sectors, and managing the portfolio to facilitate growth and add value for all stakeholders.
  • 交易:瑪麗戈德公司(紐約證券交易所代碼:MGLD)10%的所有者尼古拉斯和梅琳達·格伯生活信託基金共購買了8萬股股票,平均價格爲1.35美元。收購這些股票的成本約爲107,760美元。
  • 發生了什麼:5月13日,Marygold Companies公佈了截至3月31日的三個月和九個月的財務業績。
  • Marygold Companies的所作所爲:Marygold Companies Inc致力於識別和收購不同領域的成熟、盈利、被低估的公司,並管理投資組合,以促進增長併爲所有利益相關者增加價值。

Standard BioTools

標準生物工具

  • The Trade: Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners FO1-MSV, LP acquired a total of 600,000 shares at an average price of $2.57. To acquire these shares, it cost around $1.54 million.
  • What's Happening: On May 8, Standard BioTools posted downbeat quarterly sales.
  • What Standard BioTools Does: Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster.
  • 交易:標準生物工具公司(納斯達克股票代碼:LAB)董事Casdin Partners FO1-MSV,LP共收購了60萬股股票,平均價格爲2.57美元。收購這些股票的成本約爲154萬美元。
  • 發生了什麼:5月8日,標準生物工具公佈了悲觀的季度銷售額。
  • 標準生物工具的作用:Standard BioTools Inc開發、製造和銷售技術,幫助生物醫學研究人員更快地尋找藥物開發。

Erasca

埃拉斯卡

  • The Trade: Erasca, Inc. (NASDAQ:ERAS) Director Alexander W. Casdin acquired a total of 80,000 shares at an average price of $2.27. The insider spent around $181,920 to buy those shares.
  • What's Happening: On May 21, Erasca announced closing of underwritten offering of common stock and full exercise of the underwriters' option to purchase additional shares.
  • What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
  • 交易:埃拉斯卡公司(納斯達克股票代碼:ERAS)董事亞歷山大·卡斯丁以2.27美元的平均價格共收購了8萬股股票。知情人士花費了約181,920美元購買了這些股票。
  • 發生了什麼:5月21日,埃拉斯卡宣佈結束普通股的承銷發行,並全面行使承銷商購買額外股票的選擇權。
  • 埃拉斯卡做什麼:Erasca Inc是一家臨床階段的精準腫瘤學公司,專注於爲RAS/MAPK路徑驅動的癌症患者發現、開發和商業化療法。

Barnwell Industries

巴恩韋爾工業

  • The Trade: Barnwell Industries, Inc. (NYSE:BRN) 10% owner Sherwood Revocable Trust acquired a total of 22,486 shares at an average price of $2.82. The insider spent around $63,329 to buy those shares.
  • What's Happening: On May 14, Barnwell Industries reported financial results for its second fiscal quarter ended March 31.
  • What Barnwell Industries Does: Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas.
  • 交易:巴恩韋爾工業公司(紐約證券交易所代碼:BRN)10%的所有者舍伍德可撤銷信託基金共收購了22,486股股票,平均價格爲2.82美元。知情人士花費了約63,329美元購買了這些股票。
  • 發生了什麼:5月14日,巴恩韋爾工業公司公佈了截至3月31日的第二財季財務業績。
  • 巴恩韋爾工業公司做什麼:巴恩韋爾工業公司是一家石油和天然氣公司。其業務領域包括收購、開發、生產和銷售石油和天然氣。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論